Market research
AGRX Agile Thrpe
NASDAQ USD Healthcare
Latest close
Loading market data…
Test a moving-average rule with historical data.
- Market cap
- 10M
- P/E ratio
- Not available
- Analyst target
- 5
- Dividend yield
- Not available
- Beta
- 1.58
Profile
Company facts
- Exchange
- NASDAQ
- Currency
- USD
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- ISIN
- US00847L1008
- Market cap
- 10M
- P/E ratio
- Not available
- Analyst target
- 5
- Dividend yield
- Not available
- Beta
- 1.58
About
About Agile Thrpe
Agile Therapeutics, Inc., a women's healthcare company, engages in the research, development, and commercialization of prescription contraceptive products for women in the United States. It offers Twirla, a once-weekly prescription combination hormonal contraceptive patch. The company is also developing a pipeline of Twirla line extensions and other products, including AG200-15 Extended Regimen (ER), a regimen that allows a woman to have four episodes of withdrawal bleeding per year; AG200-15 smaller patch (SmP), which is a regimen designed to provide shorter and lighter withdrawal bleeds, and enhance contraceptive efficacy; AG200-15 ER SmP, a regimen to allow a woman to extend the length of her contraceptive cycle, as well as have shorter and lighter withdrawal bleeding episodes per year; and P-Patch, a progestin-only contraceptive patch intended for use by women who are unable or unwilling to take estrogen. Agile Therapeutics, Inc. was incorporated in 1997 and is headquartered in Princeton, New Jersey. As of August 26, 2024, Agile Therapeutics, Inc. operates as a subsidiary of Exeltis USA, Inc.
Visit company websiteCommunity
Investor discussion
1 comment
Sign in to join the AGRX discussion.
5 years, 4 months ago
Agile Therapeutics, Inc is currently in a long term downtrend where the price is trading 47.5% below its 200 day moving average.
From a valuation standpoint, the stock is 81.7% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 245.3.
Agile Therapeutics, Inc's total revenue rose by inf% to $749K since the same quarter in the previous year.
Its net income has dropped by 192.6% to $-18M since the same quarter in the previous year.
Finally, its free cash flow fell by 421.2% to $-17M since the same quarter in the previous year.
Based on the above factors, Agile Therapeutics, Inc gets an overall score of 2/5.